Comparative studies could alter coverage offerings.
PCORI spent the last year getting organized, hammering out definitions and seeking advice from all corners of the healthcare community, as required by health reform legislation. It aims to award initial grants this fall to start identifying medical products and practices with superior patient outcomes.
Added funds will evaluate strategies for improving healthcare systems and for assessing CER methods. In assessing projects, PCORI will weigh potential impact on medical practice and patient adherence, as well as prospects for reducing excessive care and costs. Although PCORI is constrained from using CER to make specific payment recommendations, researchers could evaluate how patient response would be affected by out-of-pocket outlays and other economic factors.
Strategies for ensuring the validity of observational studies and generalizability of data to broader populations are important for insurers looking to incorporate CER into reimbursement models. In addition to costs, payers are considering whether a new treatment demonstrates improvement over existing care and if clinicians will follow guidelines for appropriate use. Experts at the World Health Care Congress in April noted the need for CER in making value-based coverage decisions, particularly where randomized clinical trials are not possible.
TREATMENT FOR SUBGROUPS
Yet, Naomi Aronson, executive director of the BlueCross BlueShield Technology Evaluation Center, sees significant obstacles to assessing outcomes and their impact on health. Treatment affordability is key, she says. Even if a comparative study can document that some patients fare better on a certain therapy, the healthcare system might not be able to afford it.
Meanwhile, the quest for more patient subgroup analysis raises concerns among researchers and biopharmaceutical companies that larger and more costly CER studies will stifle innovation. To reduce outlays and risks, insurers, pharmacy benefit managers and drug makers are forming partnerships to evaluate a range of real-world strategies for treating patient subgroups and assessing diseases.
An important role for PCORI is to co-ordinate CER activities to avoid redundancies. Dissemination of results is key to drive findings into practice. PCORI will support communication activities by the Agency for Healthcare Research and Quality, which issues reports on effective treatments.
Jill Wechsler, a veteran reporter, has been covering Capitol Hill since 1994.
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More